Immunomodulatory Activity of VEGF in Cancer

International Review of Cell and Molecular Biology

Volumn 330, Issue , 2017, Pages 295-342

  Lapeyre Prost, A ^a   Terme, M ^a   Pernot, S ^a,b   Pointet, A L ^a,b   Voron, T ^a,b   Tartour, E ^a,b   Taieb, J ^a,b  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antiangiogenic therapy; Cancer; Immunotherapy; PD 1 T cells; Regulatory T cells; Tumor induced immunosuppression; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; FLUOROURACIL; INTERLEUKIN 10; OXALIPLATIN; RAMUCIRUMAB; RECOMBINANT VASCULOTROPIN; REGORAFENIB; ROCAPULDENCEL T; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; IMMUNOLOGIC FACTOR;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EFFECTOR CELL; EXON; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MACROPHAGE; MALIGNANT NEOPLASM; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; NEOPLASM;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85009188385     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.ircmb.2016.09.007     Document Type: Chapter

References (264)

1. Adotevi, O., Tartour, E., A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33:9 (2010), 991–998.
2. Alfaro, C., Perez-Gracia, J.L., Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100:7 (2009), 1111–1119.
3. Almand, B., Gabrilovich, D.I., Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6:5 (2000), 1755–1766.
4. Almand, B., Gabrilovich, D.I., Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:1 (2001), 678–689.
5. Amato, R.J., Harrop, R., Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 16:22 (2010), 5539–5547.
6. Amin, A., Figlin, R.A., Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer, 3, 2015, 14.
7. Backen, A., Jayson, G.C., The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin. Cancer Res. 20:17 (2014), 4549–4558.
8. Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow?. Lancet 357:9255 (2001), 539–545.
9. Banchereau, J., Steinman, R.M., Dendritic cells and the control of immunity. Nature 392:6673 (1998), 245–252.
10. Benjamin, L.E., Keshet, E., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:2 (1999), 159–165.
11. Bennouna, J., Kubisha, S., Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14:1 (2013), 29–37.
12. Berger, D.P., Fiebig, H.H., Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann. Oncol. 6:8 (1995), 817–825.
13. Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3:6 (2003), 401–410.
14. Bertolini, F., Kerbel, R.S., The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6:11 (2006), 835–845.
15. Bingle, L., Lewis, C.E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196:3 (2002), 254–265.
16. Birkeland, S.A., Pukkala, E., Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int. J. Cancer 60:2 (1995), 183–189.
17. Bogdan, C., Nathan, C., Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10a. Ann. N. Y. Acad. Sci. 685:1 (1993), 713–739.
18. Borghaei, H., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639.
19. Bornstein, S., McWeeney, S., IL-10 and integrin signaling pathways are associated with head and neck cancer progression. BMC Genomics, 17(1), 2016, 1.
20. Bose, A., Storkus, W.J., Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer 129:9 (2011), 2158–2170.
21. Brabletz, T., Serfling, E., Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell. Biol. 13:2 (1993), 1155–1162.
22. Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5:8 (2005), 641–654.
23. Brunda, M.J., Gately, M.K., Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:4 (1993), 1223–1230.
24. Burke, B., Lewis, C.E., Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163:4 (2003), 1233–1243.
25. Burnet, M., Cancer—a biological approach: I. The processes of control. II. The significance of somatic mutation. Br. Med. J., 1(5022), 1957, 779.
26. Busse, A., Keilholz, U., Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur. J. Cancer 47:5 (2011), 690–696.
27. Byrne, A.M., Harmey, J.H., Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 9:4 (2005), 777–794.
28. Cao, M., Liu, C., Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91:4 (2011), 598–608.
29. Cao, Y., Mukhopadhyay, D., VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:16 (2012), 3912–3918.
30. Carmeliet, P., Nagy, A., Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:6573 (1996), 435–439.
31. Casares, N., Lasarte, J.J., CD4 +/CD25 + regulatory cells inhibit activation of tumor-primed CD4 + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171:11 (2003), 5931–5939.
32. Chaput, N., Taieb, J., Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue. Gut 58:4 (2009), 520–529.
33. Chaudhary, B., Elkord, E., Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert. Opin. Ther. Targets 19:2 (2015), 147–161.
34. Chaux, P., Martin, F., Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72:4 (1997), 619–624.
35. Chen, W., Wahl, S.M., Conversion of peripheral CD4 + CD25 − naive T cells to CD4 + CD25 + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198:12 (2003), 1875–1886.
36. Chen, L., Dana, M.R., Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10:8 (2004), 813–815.
37. Chen, M.L., Cheng, A.L., Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int. J. Cancer 134:2 (2014), 319–331.
38. Cheng, A.L., Guan, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:1 (2009), 25–34.
39. Chouaib, S., Blay, J.Y., The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:10 (1997), 493–497.
40. Chow, L.Q., Eckhardt, S.G., Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25:7 (2007), 884–896.
41. Clarke, S.L., Godkin, A.J., CD4 + CD25 + FOXP3 + regulatory T cells suppress antitumor immune responses in patients with colorectal cancer. PLoS One, 1(1), 2006, e129.
42. Collinson, F., Banks, R.E., Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin. Cancer Res. 19:18 (2013), 5227–5239.
43. Coussens, L.M., Werb, Z., Inflammatory cells and cancer think different!. J. Exp. Med. 193:6 (2001), F23–F26.
44. Curiel, T.J., Zou, W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:9 (2004), 942–949.
45. Dall'Oglio, M.F., Srougi, M., Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy. Int. Braz. J. Urol. 37:2 (2011), 180–186.
46. Dellapasqua, S., Colleoni, M., Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26 (2008), 4899–4905.
47. Demetri, G.D., Casali, P.G., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:9544 (2006), 1329–1338.
48. Desar, I.M., de Vries, I., Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 129:2 (2011), 507–512.
49. Diaz-Montero, C.M., Montero, A.J., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:1 (2009), 49–59.
50. Dikov, M.M., Carbone, D.P., Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174:1 (2005), 215–222.
51. Dinapoli, M.R., Lopez, D.M., The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J. Exp. Med. 183:4 (1996), 1323–1329.
52. Dirkx, A.E., Griffioen, A.W., Antiangiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20:6 (2006), 621–630.
53. Di Salvo, J., Thomas, K.A., Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J. Biol. Chem. 270:13 (1995), 7717–7723.
54. Draghiciu, O., Daemen, T., Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4(1), 2015, e954829.
55. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4:1 (2004), 11–22.
56. Dvorak, H.F., Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146(5), 1995, 1029.
57. Eerola, A.K., Pääkkö, P., A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6:5 (2000), 1875–1881.
58. Emblem, K.E., Sorensen, A.G., Vessel architectural imaging identifies cancer patient responders to antiangiogenic therapy. Nat. Med. 19:9 (2013), 1178–1183.
59. Escors, D., Tumour immunogenicity, antigen presentation, and immunological barriers in cancer immunotherapy. New. J. Sci., 2014, 2014, 2014.
60. Escudier, B., Bukowski, R.M., Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356:2 (2007), 125–134.
61. Farace, F., Soria, J.C., Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann. Oncol. 18 (2007), 1421–1422.
62. Farsaci, B., Hodge, J.W., Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 130:8 (2012), 1948–1959.
63. Ferrara, N., Moore, M.W., Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996), 439–442.
64. Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor. Endocr. Rev. 18:1 (1997), 4–25.
65. Ferrara, N., Alitalo, K., Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5:12 (1999), 1359–1364.
66. Ferrara, N., Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280:6 (2001), C1358–C1366.
67. Figlin, R.A., Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opin. Biol. Ther. 15:8 (2015), 1241–1248.
68. Fingleton, B., Matrisian, L.M., Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3:6 (2001), 459–468.
69. Finke, J.H., Bukowski, R., Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14:20 (2008), 6674–6682.
70. Finke, J.H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., Bukowski, R., Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14:20 (2008), 6674–6682.
71. Fiorentino, D.F., O'garra, A., IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:11 (1991), 3815–3822.
72. Folkman, J., Williams, G., Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133:2 (1971), 275–288.
73. Fondevila, C., Pera, M., p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br. J. Cancer 90:1 (2004), 206–215.
74. Fong, G.H., Breitman, M.L., Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:6535 (1995), 66–70.
75. Freeman, M.R., Klagsbrun, M., Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55:18 (1995), 4140–4145.
76. Fraser, H.M., Bicknell, R., Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor 1. Endocrinology 141:3 (2000), 995–1000.
77. Fuh, G., de Vos, A.M., The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 275:35 (2000), 26690–26695.
78. Fukunaga, A., Katoh, H., CD8 + tumor-infiltrating lymphocytes together with CD4 + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:1 (2004), e26–e31.
79. Gabrilovich, D., Carbone, D.P., Dendritic cells in antitumor immune responses: I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170:1 (1996), 101–110.
80. Gabrilovich, D.I., Carbone, D.P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:10 (1996), 1096–1103.
81. Gabrilovich, D.I., Carbone, D.P., Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3:3 (1997), 483–490.
82. Gabrilovich, D., Carbone, D.P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:11 (1998), 4150–4166.
83. Gabrilovich, D.I., Carbone, D.P., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5:10 (1999), 2963–2970.
84. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.H., Trajanoski, Z., Fridman, W.H., Pagès, F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:5795 (2006), 1960–1964.
85. Gao, Q., Tang, Z.Y., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25:18 (2007), 2586–2593.
86. Garcia, J.A., Rini, B.I., Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 107:4 (2011), 562–570.
87. Gatti, R.A., Good, R.A., Occurrence of malignancy in immunodeficiency diseases: a literature review. Cancer 28:1 (1971), 89–98.
88. Gavalas, N.G., Bamias, A., VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 107:11 (2012), 1869–1875.
89. Gazzinelli, R.T., Sher, A.L.A.N., IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J. Immunol. 148:6 (1992), 1792–1796.
90. Geissmann, F., Durandy, A., TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162:8 (1999), 4567–4575.
91. Gerber, H.P., Ferrara, N., VEGF is required for growth and survival in neonatal mice. Development 126:6 (1999), 1149–1159.
92. Gerber, H.P., Ferrara, N., VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:6 (1999), 623–628.
93. Ghiringhelli, F., Zitvogel, L., CD4 + CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202:8 (2005), 1075–1085.
94. Ghiringhelli, F., Zitvogel, L., Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4 + CD25 + regulatory T cell proliferation. J. Exp. Med. 202:7 (2005), 919–929.
95. Giantonio, B.J., Benson, A.B., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25:12 (2007), 1539–1544.
96. Gibson, H.M., Wong, H.K., Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J. Immunol. 179:6 (2007), 3831–3840.
97. Gotlieb, W.H., Martínez-Maza, O., Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4:5 (1992), 385–390.
98. Grothey, A., Laurent, D., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:9863 (2013), 303–312.
99. Hamerlik, P., Bartek, J., Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 209:3 (2012), 507–520.
100. Hamid, O., Ribas, A., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:2 (2013), 134–144.
101. Hamzah, J., Ganss, R., Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453:7193 (2008), 410–414.
102. Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100:1 (2000), 57–70.
103. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
104. Hansen, W., Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma. Oncoimmunology, 2(2), 2013, e23039.
105. Hattori, K., Rafii, S., Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1 + stem cells from bone-marrow microenvironment. Nat. Med. 8:8 (2002), 841–849.
106. Heckel, M.C., Platsoucas, C.D., Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell. Immunol. 266:2 (2011), 143–153.
107. Heng, D.Y., Choueiri, T.K., Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27:34 (2009), 5794–5799.
108. Herbst, R.S., Hainsworth, J., Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:9780 (2011), 1846–1854.
109. Hiraoka, N., Hirohashi, S., Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12:18 (2006), 5423–5434.
110. Hodi, F.S., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:8 (2010), 711–723.
111. Hoechst, B., Korangy, F., Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:3 (2009), 799–807.
112. Houck, K.A., Ferrara, N.J., Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267:36 (1992), 26031–26037.
113. Huang, A.Y., Levitsky, H.I., Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?. J. Exp. Med. 183:3 (1996), 769–776.
114. Huang, B., Chen, S.H., Gr-1 + CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:2 (2006), 1123–1131.
115. Huang, Y., Carbone, D.P., Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110:2 (2007), 624–631.
116. Huang, D., Teh, B.T., Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70:3 (2010), 1063–1071.
117. Huang, Y., He, Y., Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J. Cancer Res. Clin. Oncol. 137:5 (2011), 829–837.
118. Huang, Y., Poznansky, M.C., Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109:43 (2012), 17561–17566.
119. Huang, C.T., Vignali, D.A.A., Role of LAG-3 in regulatory T cells. Immunity 21:4 (2004), 503–513.
120. Huang, K.W., Wu, H.L., Lin, H.L., Liang, P.C., Chen, P.J., Chen, S.H., Lee, H.I., Su, P.Y., Wu, W.H., Lee, P.H., Hwang, L.H., Chen, D.S., Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc. Natl. Acad. Sci. U.S.A. 107:33 (2010), 14769–14774.
121. Hurwitz, H., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:23 (2004), 2335–2342.
122. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:5706 (2005), 58–62.
123. Jaini, R., Tuohy, V.K., Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int. J. Cancer 134:7 (2014), 1695–1705.
124. Kanno, S., Sato, Y., Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:17 (2000), 2138–2146.
125. Kantoff, P.W., Schellhammer, P.F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:5 (2010), 411–422.
126. Kaplan, D.H., Schreiber, R.D., Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95:13 (1998), 7556–7561.
127. Kärre, K., Kiessling, R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:6055 (1986), 675–678.
128. Katoh, O., Satow, Y., Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:23 (1995), 5687–5692.
129. Kim, K.J., Ferrara, N., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993), 841–844.
130. Kim, R., Arihiro, K., Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66:11 (2006), 5527–5536.
131. Klement, G., Kerbel, R.S., Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8:1 (2002), 221–232.
132. Ko, J.S., Cohen, P.A., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70:9 (2010), 3526–3536.
133. Ko, J.S., Finke, J.H., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15:6 (2009), 2148–2157.
134. Kohga, K., Hayashi, N., Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 51:4 (2010), 1264–1273.
135. Kondo, S., Suzuki, H., Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta 1221:2 (1994), 211–214.
136. Kopetz, S., Heymach, J.V., Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28:3 (2010), 453–459.
137. Koreth, J., Soiffer, R., Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365:22 (2011), 2055–2066.
138. Kondratiev, S., Resnick, M.B., Intratumoral CD8 + T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 10:13 (2004), 4450–4456.
139. Krusch, M., Salih, H.R., The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J. Immunol. 183:12 (2009), 8286–8294.
140. Kujawski, M., Yu, H., Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70:23 (2010), 9599–9610.
141. Kusmartsev, S., Gabrilovich, D.I., Tumor-associated CD8 + T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175:7 (2005), 4583–4592.
142. Kusmartsev, S., Vieweg, J., Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181:1 (2008), 346–353.
143. Lange, T., Neufeld, G., VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J. Biol. Chem. 278:19 (2003), 17164–17169.
144. Lee, Y.J., Benveniste, E.N., TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158:5 (1997), 2065–2075.
145. Lee, S., Iruela-Arispe, M.L., Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:4 (2007), 691–703.
146. Levy, N.S., Levy, A.P., Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273:11 (1998), 6417–6423.
147. Lewis, J.S., Lewis, C.E., Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192:2 (2000), 150–158.
148. Li, B., Jooss, K., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12:22 (2006), 6808–6816.
149. Li, H., Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J. Immunol. 182:1 (2009), 240–249.
150. Linde, N., Mueller, M.M., Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J. Pathol. 227:1 (2012), 17–28.
151. MacKie, R.M., Junor, B., Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348:6 (2003), 567–568.
152. Manning, E.A., Emens, L.A., A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13:13 (2007), 3951–3959.
153. Mantovani, A., Ruco, L., The origin and function of tumor-associated macrophages. Immunol. Today 13:7 (1992), 265–270.
154. Manzoni, M., Danova, M., Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79:3–4 (2010), 187–196.
155. Marigo, I., Bronte, V., Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222:1 (2008), 162–179.
156. Matsuda, M., Kiessling, R., Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180:6 (1994), 2371–2376.
157. Matsumoto, S., Krishna, M.C., Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 71:20 (2011), 6350–6359.
158. Mazzoni, A., Segal, D.M., Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:2 (2002), 689–695.
159. Mehrotra, S., Kiessling, R., Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv. Cancer Res. 102 (2009), 197–227.
160. Melani, C., Colombo, M.P., Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102:6 (2003), 2138–2145.
161. Melnyk, O., Shuman, M., Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 161:3 (1999), 960–963.
162. Melter, M., Briscoe, D.M., Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96:12 (2000), 3801–3808.
163. Mesiano, S., Jaffe, R.B., Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153:4 (1998), 1249–1256.
164. Miller, K., Davidson, N.E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357:26 (2007), 2666–2676.
165. Mimura, K., Fujii, H., Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother. 56:6 (2007), 761–770.
166. Mineo, T.C., Tonini, G., Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer. J. Clin. Pathol. 57:6 (2004), 591–597.
167. Mizukami, Y., Chung, D.C., Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11:9 (2005), 992–997.
168. Mlecnik, B., Galon, J., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29:6 (2011), 610–618.
169. Molhoek, K.R., Slingluff, C.L. Jr., Apoptosis of CD4 + CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol. Immunother. 58:6 (2009), 867–876.
170. Moser, M., Dendritic cells in immunity and tolerance—do they display opposite functions?. Immunity 19:1 (2003), 5–8.
171. Motzer, R.J., Basch, E., Targeted drugs for metastatic renal cell carcinoma. Lancet 370:9605 (2007), 2071–2073.
172. Motzer, R.J., Rini, B.I., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24:1 (2006), 16–24.
173. Motzer, R.J., Sharma, P., Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373:19 (2015), 1803–1813.
174. Mougiakakos, D., Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers 3:2 (2011), 1708–1731.
175. Nagai, H., Sumino, Y., Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. Clin. Dev. Immunol., 2012, 2012, 607851.
176. Nagaraj, S., Gabrilovich, D.I., Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer. Nat. Med. 13:7 (2007), 828–835.
177. Nagy, J.A., Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196:11 (2002), 1497–1506.
178. Nakamura, I., Takenoshita, S., Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol. Lett. 5:5 (2013), 1682–1686.
179. Nefedova, Y., Gabrilovich, D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:1 (2004), 464–474.
180. Nestle, F.O., Nickoloff, B.J., Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 150(2), 1997, 641.
181. Nicosia, R.F., Qian, X., Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol., 151(5), 1997, 1379.
182. Nikolinakos, P.G., Heymach, J.V., Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 70:6 (2010), 2171–2179.
183. Norden-Zfoni, A., Heymach, J.V., Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13:9 (2007), 2643–2650.
184. O'Connor, J.P., Jayson, G.C., Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?. Clin. Cancer Res. 18:24 (2012), 6588–6598.
185. Oestreich, K., Boss, J.M., NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181:7 (2008), 4832–4839.
186. Ohm, J.E., Carbone, D.P., VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:12 (2003), 4878–4886.
187. Onesto, C., Pagès, G., Poly (A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J. Biol. Chem. 279:33 (2004), 34217–34226.
188. Osada, T., Mose, M.A., The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57:8 (2008), 1115–1124.
189. Oshikiri, T., Katoh, H., Prognostic value of intratumoral CD8 + T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J. Surg. Oncol. 84:4 (2003), 224–228.
190. Oyama, T., Gabrilovich, D.I., Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160:3 (1998), 1224–1232.
191. Ozao-Choy, J., Chen, S.H., The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69:6 (2009), 2514–2522.
192. Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.H., Trajanoski, Z., Fridman, W.H., Galon, J., Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353:25 (2005), 2654–2666.
193. Park, J.E., Ferrara, N., The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4:12 (1993), 1317–1326.
194. Park, H.J., Ha, S.J., Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell. Immunol. 278:1 (2012), 76–83.
195. Pasche, B., Role of transforming growth factor beta in cancer. J. Cell. Physiol. 186:2 (2001), 153–168.
196. Penn, I., Post-transplant malignancy. Drug Saf. 23:2 (2000), 101–113.
197. Pepper, M.S., Montesano, R., Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. 32:3 (1990), 319–327.
198. Pepper, M.S., Montesano, R., Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:2 (1991), 902–906.
199. Pepper, M.S., Montesano, R., Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189:2 (1992), 824–831.
200. Pere, H., Tartour, E., A CCR4 antagonist combined with vaccines induces antigen-specific CD8 + T cells and tumor immunity against self antigens. Blood 118:18 (2011), 4853–4862.
201. Perrotte, P., Dinney, C.P., Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5:2 (1999), 257–264.
202. Pisa, P., Kiessling, R., Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. U.S.A. 89:16 (1992), 7708–7712.
203. Plouët, J., Bayard, F., Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 272:20 (1997), 13390–13396.
204. Prior, J.O., Leyvraz, S., Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol. 27:3 (2009), 439–445.
205. Presta, L.G., Ferrara, N., Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:20 (1997), 4593–4599.
206. Rak, J., Kerbel, R.S., Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 5:1 (2000), 24–33 Nature Publishing Group.
207. Robert, L., Hu-Lieskovan, S., Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Semin. Immunol. 28 (2016), 73–80 Academic Press.
208. Roberts, W.G., Palade, G.E., Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108:6 (1995), 2369–2379.
209. Robertson, M.J., Ritz, J., Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1:1 & 2 (1996), 88–97.
210. Rodriguez, P.C., Ochoa, A.C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:4 (2009), 1553–1560.
211. Rolny, C., Claesson-Welsh, L., HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:1 (2011), 31–44.
212. Russell, J.H., Ley, T.J., Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:1 (2002), 323–370.
213. Sakaguchi, S., Naturally arising CD4 + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004), 531–562.
214. Sakuishi, K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J. Exp. Med. 207:10 (2010), 2187–2194.
215. Samuel, S., Ellis, L.M., Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30:10 (2011), 1205–1212.
216. Sandler, A., Johnson, D.H., Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355:24 (2006), 2542–2550.
217. Sato, E., Odunsi, K., Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102:51 (2005), 18538–18543.
218. Sawano, A., Shibuya, M., Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97:3 (2001), 785–791.
219. Schumacher, K., Schlag, P.M., Prognostic significance of activated CD8 + T cell infiltrations within esophageal carcinomas. Cancer Res. 61:10 (2001), 3932–3936.
220. Schweighofer, B., Hofer, E., The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb. Haemost., 102(3), 2009, 544.
221. Serafini, P., Borrello, I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:13 (2008), 5439–5449.
222. Shalaby, F., Schuh, A.C., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:6535 (1995), 62–66.
223. Shankaran, V., Schreiber, R.D., IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:6832 (2001), 1107–1111.
224. Sharma, P., Sato, E., CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. U.S.A. 104:10 (2007), 3967–3972.
225. Shrimali, R.K., Rosenberg, S.A., Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70:15 (2010), 6171–6180.
226. Sinha, P., Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:2 (2007), 977–983.
227. Smyth, M.J., Godfrey, D.I., Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:4 (2000), 661–668.
228. Smyth, M.J., Thia, K.Y., Street, S.E., MacGregor, D., Godfrey, D.I., Trapani, J.A., Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192:5 (2000), 755–760.
229. Soker, S., Klagsbrun, M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:6 (1998), 735–745.
230. Strauss, D.C., Thomas, J.M., Transmission of donor melanoma by organ transplantation. Lancet Oncol. 11:8 (2010), 790–796.
231. Strawn, L.M., Shawver, L.K., Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:15 (1996), 3540–3545.
232. Suarez, S.C., Ballmer-Hofer, K., A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 63:17 (2006), 2067–2077.
233. Suzuki, H., Katano, M., VEGFR2 is selectively expressed by FOXP3high CD4 + Treg. Eur. J. Immunol. 40:1 (2010), 197–203.
234. Suzuki, H., Katano, M., Intratumoral FOXP3 + VEGFR2 + regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin. Immunol. 146:1 (2013), 26–33.
235. Tabernero, J., Nasroulah, F., Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16:5 (2015), 499–508.
236. Taga, K., Tosato, G., IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol. 148:4 (1992), 1143–1148.
237. Taieb, J., Zitvogel, L., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176:5 (2006), 2722–2729.
238. Takahashi, H., Shibuya, M., The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109:3 (2005), 227–241.
239. Terme, M., Taieb, J., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73:2 (2013), 539–549.
240. Thomas, L., On immunosurveillance in human cancer. Yale J. Biol. Med., 55(3–4), 1982, 329.
241. Tsavaris, N., Baxevanis, C.N., Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. Invest. New Drugs 30:1 (2012), 395–402.
242. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:26 (2012), 2443–2454.
243. Tosolini, M., Galon, J., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71:4 (2011), 1263–1271.
244. Tseng, P.L., Hu, T.H., Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J. Surg. Oncol. 98:5 (2008), 349–357.
245. Unemori, E.N., Amento, E.P., Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol. 153:3 (1992), 557–562.
246. Van Cutsem, E., Allegra, C., Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30 (2012), 3499–3506.
247. Veikkola, T., Alitalo, K., Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20:6 (2001), 1223–1231.
248. Vincent, J., Ghiringhelli, F., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:8 (2010), 3052–3061.
249. Voron, T., Terme, M., VEGF-A modulates expression of inhibitory checkpoints on CD8 + T cells in tumors. J. Exp. Med. 212:2 (2015), 139–148.
250. Vukmanovic-Stejic, M., Akbar, A.N., Human CD4 + CD25 hi Foxp3 + regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116:9 (2006), 2423–2433.
251. Wada, Y., Kojiro, M., Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:2 (1998), 407–414.
252. Wada, J., Katano, M., The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 29:3 (2009), 881–888.
253. de Waal Malefyt, R., de Vries, J.E., Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:5 (1991), 1209–1220.
254. Whitaker, G.B., Rosenbaum, J.S., Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121. J. Biol. Chem. 276:27 (2001), 25520–25531.
255. Wilhelm, S., Kelley, S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5:10 (2006), 835–844.
256. Wilke, H., Ohtsu, A., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15:11 (2014), 1224–1235.
257. Wing, K., Sakaguchi, S., CTLA-4 control over Foxp3 + regulatory T cell function. Science 322:5899 (2008), 271–275.
258. Wolf, A.M., Grubeck-Loebenstein, B., Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9:2 (2003), 606–612.
259. Woolard, J., Bates, D.O., VEGF165b, an inhibitory vascular endothelial growth factor splice variant mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64:21 (2004), 7822–7835.
260. Xin, H., Yu, H., Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69:6 (2009), 2506–2513.
261. Zea, A.H., Ochoa, A.C., l-Arginine modulates CD3ζ expression and T cell function in activated human T lymphocytes. Cell. Immunol. 232:1 (2004), 21–31.
262. Zhao, W., Xu, Q., Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22:6 (2008), 1226–1233.
263. Ziogas, A.C., Bamias, A., VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int. J. Cancer 130:4 (2012), 857–864.
264. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5:4 (2005), 263–274.